I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1.GLOBAL OUTLOOK
Rising Incidences of Glaucoma Demands Novel Medications
Understanding of Treatment Patterns Imperative for Developing New Drugs
How Widespread is the Disease?
Table 1: Worldwide Glaucoma Prevalence by Select Countries (includes corresponding Graph/Chart)
Aging Population & Environmental Factors Drive Growth
Combination Drugs Become Mainstay Glaucoma Products
Is Marijuana A Potential Cure?
Lack of Awareness Among Patients – A Prevailing Trend
High Costs Discourage Patients from Receiving Treatment
The All-Consuming Issue of Compliance
Competitive Landscape
Table 2: Global Market for Glaucoma Pharmaceuticals (2008): Percentage Value Share Breakdown of Leading Players - Pfizer, Inc., Allergan, Inc., Merck & Co., Alcon, Ista Pharmaceuticals and Others (includes corresponding Graph/Chart)
Current and Future Analysis
2.AN OVERVIEW OF GLAUCOMA DISORDER
A Prelude
Who’s At Risk?
Leading Causes for Glaucoma
Diagnosis
Symptom Free Progression: A Major Concern
Types of Glaucoma
Primary Glaucoma
Primary Open-Angle Glaucoma (POAG)
Acute Angle-Closure Glaucoma (AACG)
Developmental Glaucoma
Secondary Glaucoma
Other Common Types of Glaucoma
Pigmentary Glaucoma
Pseudo-Exfoliation Glaucoma
Neovascular Glaucoma
Toxic Glaucoma
3.AN OVERVIEW OF GLAUCOMA TREATMENT
Glaucoma Treatment Strategies
Drugs Used for Treating Glaucoma
A Quick Look at Major Drugs by Category
Beta-Adrenergic Blockers or "Beta Blockers"
Profile of Major Drugs under the Category
Timolol
Levobunolol
Carteolol
Metipranolol
Betaxolol
Side Effects of Beta-Blockers
Alpha-Adrenergic Agonists
Side Effects of Alpha-Adrenergic Agonists
Carbonic Anhydrase Inhibitors
Profile of Major Drugs under the Category
Acetazolamide
Dorzolamide
Side Effects of Carbonic Anhydrase Inhibitors
Prostaglandin Analogues
Side Effects of Prostaglandin Analogues
Miotics
Side Effects of Miotics
Epinephrine Compounds
Mydriatics & Cycloplegics
Commercial Mydriatic-Cycloplegics
Side Effects of Mydriatic-Cycloplegics
Neuroprotective Drugs
Surgical Approach to Glaucoma Treatment
Laser Surgery
Laser Trabeculoplasty
Argon Laser Trabeculoplasty (ALT)
Selective Laser Trabeculoplasty (SLT)
Laser Peripheral Iridotomy (LPI)
Filtering Procedure
Trabeculectomy
Drainage Implant Surgery
Other Surgical Procedures
Non-Penetrating Surgery
Canaloplasty
The Express Mini Glaucoma Shunt
Trabectome
4.SELECT NEW DRUG APPROVALS
Novagali Obtains FDA Approval for Catioprost Phase III Trial
X-Gen Obtains FDA Approval for Acetazolamide Injection
Alcon Obtains EMEA Approval for Azarga® Ophthalmic Suspension
Santen Receives Clearance for Tapros™ in Japan
Santen Obtains Marketing Clearance for Taflotan™ in Denmark
Allergan Obtains FDA Clearance for Combigan
Alcon Receives Japanese Approval for Travatanz™ Solution
5.RECENT INDUSTRY ACTIVITY
Alcon to Take Over Swiss Biotech Company, ESBATech
Abbott Acquires Advanced Medical Optics
Aton Pharma Purchases US Marketing Rights to Merck 's Timoptic
NicOx to Re-Acquire Rights to Glaucoma Drug from Pfizer
Merck Inks Licensing Deal for Tafluprost with Santen
Sucampo Inks In-licensing Deal with R-Tech for Rescula
Alcon Commences Construction of Pharmaceutical Manufacturing Facility
Alcon Abandons Anecortave Acetate Development
Pipex to Acquire Rights to Additional Usage of Oral Flupirtine
Othera Submits IND Application with FDA for OT-730
Inspire Commences Phase I Trial of Glaucoma Candidate, INS117548
Lexicon Begins Preclinical Development of LX7101 for Glaucoma
Pipex Pharmaceuticals Changes Name to Adeona Pharmaceuticals
Warburg Pincus Acquires Bausch & Lomb
Santen and R-Tech Extend Marketing Agreement for RESCULA® in Japan
6.FOCUS ON SELECT GLOBAL PLAYERS
Acadia Pharmaceuticals, Inc. (US)
Alcon Laboratories, Inc. (US)
Allergan, Inc. (US)
Falcon Pharmaceuticals, Ltd. (US)
Inotek Pharmaceuticals Corporation (US)
Inspire Pharmaceuticals, Inc. (US)
Lexicon Pharmaceuticals, Inc. (US)
Merck & Co., Inc. (US)
NicOx S.A. (France)
Novartis International AG (Switzerland)
Pfizer, Inc. (US)
Santen Pharmaceutical Co., Ltd. (Japan)
7.GLOBAL MARKET PERSPECTIVE
Table 3: World Recent Past, Current & Future Analysis for Glaucoma Pharmaceuticals Market by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 4: World 10-year Perspective for Glaucoma Pharmaceuticals Market by Geographic Region – Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2006, 2009 & 2015
III. MARKET
1.UNITED STATES
A. Market Analysis
Glaucoma Market: A Quick Primer
Table 5: Glaucoma Pharmaceutical Products Prescription Volume in the US (2008 & 2009): Percentage Breakdown for Xalatan, Lumigan, Alphagan P, Travatan and Others (includes corresponding Graph/Chart)
Prevalence of Glaucoma – A Recapitulation of Facts
Patent Expiries to Prune Glaucoma Market Size
Patent Expiries of Key Glaucoma Drugs in Recent Past, Current, and Future
Leading Drugs to Lose Sheen
Table 6: Leading Glaucoma Pharmaceutical Products in the US (2008, 2010 & 2012): Percentage Breakdown of Value Sales for Xalatan/Xalcom, Cosopt, Lumigan, Travatan, Alphagan, Combigan, Generic Timolol and Others (includes corresponding Graph/Chart)
Research & Development
Select Combination Therapeutics in Pipeline
Ganfort (Lumigan/timolol) – Pending Approval
DuoTrav (Travatan/timolol) – Pending Approval
Xalcom (Xalatan/timolol) – Pending Approval
Azopt (brinzolamide/timolol) – Phase III
Travatan/Azopt – Phase III
Pipeline Directory of Glaucoma Pharmaceuticals in the US (As of March 2009)
Select Glaucoma Pharmaceuticals in Phase III Clinical Studies
Select Glaucoma Pharmaceuticals in Phase II Clinical Studies
Select Glaucoma Pharmaceuticals in Phase I Clinical Studies
Select New Drug Approvals
Strategic Corporate Developments
Select Players in the Region
B. Market Analytics
Table 7: US Recent Past, Current & Future Analysis for Glaucoma Pharmaceuticals Market by Drug Class – Alpha Adrenergic Agonists, Beta-Blockers, Carbonic Anhydrase Inhibitors, Combination Therapies, Prostaglandin Analogues and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 8: US 10-Year Perspective for Glaucoma Pharmaceuticals by Drug Class – Percentage Breakdown of Dollar Sales for Alpha Adrenergic Agonists, Beta-Blockers, Carbonic Anhydrase Inhibitors, Combination Therapies, Prostaglandin Analogues and Other Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
2.REST OF WORLD
A. Market Analysis
Combination Drugs and Generics to Gain Traction
Table 9: Leading Glaucoma Pharmaceutical Products in Rest of World Market (2008, 2010 & 2012): Percentage Breakdown of Value Sales for Xalatan/Xalcom, Cosopt/Trusopt, Travatan/Extravan, Lumigan/ Ganfort, Alphagan/Combigan, Timoptic/ XE, Generic Timolol and Others (includes corresponding Graph/Chart)
Focus on Glaucoma Market in Select Countries
CANADA
Lack of Awareness: A Key Issue
EUROPE
Glaucoma Pharmaceuticals Reimbursement in Europe
CHINA
Select Drug Approvals
Strategic Corporate Developments
Select Players
B. Market Analytics
Table 10: Rest of World Recent Past, Current & Future Analysis for Glaucoma Pharmaceuticals – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 32 (including Divisions/Subsidiaries - 33)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Rest of Europe
Middle East